OBR Daily Commentary


Lilly Surges On Verzenio Survival Data In Early Breast Cancer

(PMLiVE [UK]) June 17, 2020 - New data with Eli Lilly’s CDK4/6 inhibitor Verzenio has sent the drug to the top of the class in patients with hormone receptor-positive, HER2-negative early-stage breast cancer.

Read Article arrow

Dean Gesme, MD (Posted: June 18, 2020)


The positive primary endpoint of improved iDFS with Abemaciclib plus adjuvant AI in this Monarch E interim evaluation stands in confusingly stark contrast to the negative efficacy reported from the preliminary PALLUS for adjuvant high risk early stage breast cancer! Could this be due to genuine differences in efficacy, differences in the study populations, or just statistical flukes in the data?



Add Comment 1 Comment(s)